A new real-world study suggests that Nefecon (targeted-release budesonide) can reduce proteinuria and help preserve kidney function in primary IgA nephropathy, including in patients who start with relatively low protein levels. The findings focus on outcomes outside tightly controlled trial settings. Reported by a team led across the study’s contributing clinicians, the research adds to evidence that targeted corticosteroid delivery to the gut-associated lymphoid tissue can translate into measurable kidney benefits. The emphasis on “real-world” response helps clinicians weigh expectations for benefit and informs discussions about earlier lines of therapy in routine practice. For the broader kidney market, the data support Nefecon’s positioning as a precision, oral option rather than a purely steroid-sparing niche product.